The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030: Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive) and Purpose of Solution (Medication Replacement and Medication Augmentation)

  • Lowest Price Guaranteed From USD 4,899

  • Published
    July 2020

  • Pages
    513

  • View Count
    8650

Example Insights

Digital-Health-Market-Context Digital-Health-Market-Example-highlight Digital-Health-Market-List-of-Digital-Therapeutic-Solutions Digital-Health-Market-Pipeline
Digital-Health-Market-Distribution-by-Status-of-Development Digital-Health-Market-Product-Competitiveness-Analysis Digital-Health-Market-Clinical-Research-Landscape Digital-Health-Market-Strategy-Matrix
Digital-Health-Market-Funding-and-Investments Digital-Health-Market-Partnerships-and-Collaborations Digital-Health-Market-Key-Marketing-Strategies Digital-Health-Market-Case-Study
Digital-Health-Market-Future-forecast Digital-Health-Market-key-geographical-regions    

Overview

The overall market for digital therapeutics is expected to be worth over a billion dollars, and is likely to evolve significantly in the near future, as more of such solutions are developed and made available. Further, a significant surge in adoption of these evidence-based solutions can be observed due to increased demand for personalized treatment options amid COVID-19 outbreak

-- Founder and CEO, a UK based small-sized company

Chronic disorders, such as arthritis, diabetes, cancer, obesity and heart disease, are considered to be the leading causes of death and disability across the world. Specifically, the global prevalence of diabetes is estimated to be more than 300 million adults by 2025. According to the WHO, more than 450 million people are presently suffering from some form of mental health disorder (such as anxiety and depression), and / or neurological disorder. The rise in number of patients suffering from such clinical conditions continues to impose a significant burden on the global healthcare system. Specifically, in the US, it was estimated that approximately 90% of the country’s annual healthcare expenditure was on patients suffering from various chronic and mental health conditions.

Digital health solutions represent a relatively new concept, which was introduced into mainstream healthcare a few years ago. Such solutions are presently believed to possess the potential to reshape the practice of healthcare. Typically, digital therapeutics are available in the form of various types of gamified solutions, and / or standalone software applications, sometimes  featuring active, personalized coaching support, or artificial intelligence (AI) enabled support. The ongoing COVID-19 pandemic and the mandatory enforcement of social distancing measures have created a significant demand for remote healthcare solutions. In fact, China introduced a range of digital solutions throughout different stages of the outbreak, immediately after the coronavirus spread.  Recently, the USFDA also issued certain guidelines on usability of digital therapeutics (specifically for psychiatric conditions), allowing patients to receive treatment at home, minimizing visits to clinics / hospitals, thereby, reducing risk of exposure to the novel coronavirus. Moreover, several companies are actively striving to create and launch solutions that not only allow patients to diagnose and confirm disease symptoms, and consult with doctors / physicians remotely, but also offer therapeutic aid. Although the focus of such companies is presently on diabetes, mental health disorders and musculoskeletal injuries, experts believe that digital therapeutics may eventually replace / augment traditional treatment measures, with clinically validated software. ,    

It is worth noting that there are several successful start-ups focused on designing and development of digital therapeutics; in fact, most such companies are backed by noteworthy investors. A number of digital health solutions are already in the market, and several other innovative solutions are under development. It is worth highlighting that for certain digital health solutions, reimbursement options are also available. In addition, several companies are focused on expanding their offerings to support the management of the COVID-19 pandemic. As the demand for digital solutions gradually rises, pioneers in this domain are likely to benefit the most from increased product sales.

Scope of the Report

The “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation))” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of digital therapeutics solutions (either commercialized or under development) in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • An overview of the current market landscape of digital therapeutic solutions, including information on status of development, type of solution (combination offering of software application + device or AI or personal coach, and standalone software application), type of therapy (curative and preventive), purpose of solution (medication replacement and medication augmentation), target indication(s), therapeutic area(s), and target population. In addition, it presents details of the companies developing digital therapeutic solution, highlighting year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters.
  • An in depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of digital therapeutic solutions based on the parameters, such as product portfolio strength, number of target indication(s) and company size, [B] a grid representation illustrating the distribution of the digital therapeutic solutions based on status of development, type of solution and therapeutic area, [C] an insightful tree map representation of the digital therapeutic solutions, distributed on the basis of therapeutic area and company size, and [D] a world map representation highlighting the regional distribution of developer companies.
  • A detailed product competitiveness analysis of digital therapeutic solutions developed / under development for the most popular therapeutic areas taking into consideration the strength of product portfolio (based on the total number of digital therapeutic solutions being developed in that disease area) and key product specific parameters, such as status of development, type of solution, type of therapy, and purpose of solution.
  • Elaborate profiles of prominent small-sized and mid-sized players that are either engaged in the development or have developed digital therapeutic solutions. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.
  • A detailed analysis of more than 220 completed, ongoing and planned clinical studies of various digital therapeutic solutions, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status and trial focus, highlighting leading sponsors and leading digital therapeutic solutions (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful clinical end-points analysis (for trials initiated since 2018 for popular therapeutic areas).
  • An analysis of the investments made in the period between 2009 and 2020 (till June), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field. 
  • An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2008 and 2020 (till May), covering marketing and distribution agreements, mergers / acquisitions, pilot product offerings, product / technology integration agreements,  product / technology licensing agreements, product development agreements, product evaluation agreements, product training agreements, research and development agreements and product development and commercialization agreements. 
  • A detailed analysis of the various business models and go-to-market strategies adopted by companies involved in this space, providing details on various channels adopted / being adopted by stakeholders in the industry to raise awareness and offer access to their proprietary products.
  • A Bowman’s Strategy Clock framework in order to analyze the competitive position of various companies in the marketplace, taking into consideration the prices and different features of their products.
  • An insightful discussion on the impact of COVID-19 pandemic on the overall digital therapeutic solutions market, and the key initiatives undertaken by big pharma players.
  • A review of the key aspects related to the remote digital monitoring and diagnostics solutions, including [A] a brief introduction to remote digital monitoring and diagnostics solutions, highlighting the key benefits and roadblocks [B] an assessment of the market landscape of remote digital monitoring and diagnostics solutions, based on various parameters, such as status of development, type of solution, target disease indication(s) and therapeutic area, along with details on the companies that develop these solutions, highlighting year of establishment, company size and location of headquarters [C] detailed profiles of some of the key players that presently offer digital monitoring / diagnostic solutions for chronic disease management; each profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters, lead investors, key partners and  members of the executive team), details of their product portfolio, recent developments and an informed future outlook, and [D] an insightful analysis on various capital investments that have been made into the digital monitoring / diagnostics domain.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall digital therapeutic solutions industry.
  • An informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till July) and insights from the recent news articles related digital therapeutic solutions, indicating the increasing popularity of this domain. Furthermore, it highlights the potential future opportunities for players engaged in development of such solutions.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for digital therapeutics developers over the next decade. Based on multiple parameters, likely adoption trends, and expected price variations for these products, we have provided an informed estimate of the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within digital therapeutics market across [A] type of solution (combination offering of software application + device or AI or personal coach, and standalone software applications), [B] purpose of solution (medication replacement and medication augmentation), [C] type of therapy (curative and preventive), [D] distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), [E] therapeutic areas (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other disorders), and [F] key geographical regions (North America (the US and Canada), Europe (France, Germany, Italy, Spain and the UK), Asia-Pacific (Australia, China, India, Japan, and South Korea) and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders: 

  • Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health) 
  • Adam Kaufman (Chief Executive Officer, Canary Health) 
  • Vijay Ravindran (Chief Executive Officer, Floreo) 
  • Eran Ofir (Chief Executive Officer, Somatix) 
  • Edouard Gasser (Chief Executive Officer, Tilak Healthcare)
  • Palakh R Sarogi (Vice President Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics)
  • Amelie Janson (Communication Manager, Voluntis) 
  • Anonymous (Founder and Chief Executive Officer, UK based Small-Sized Company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading developers offering digital therapeutic solutions?
  • What are the most popular therapeutic areas for digital therapeutic solutions?
  • Which companies are actively involved in conducting clinical trials for their solutions? 
  • What are the key factors influencing the price of digital therapeutic solutions?
  • What is the trend in capital investments in the digital therapeutics market?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What type of marketing strategies are being adopted by developers in this domain?
  • What is the impact of COVID-19 outbreak on digital therapeutic solutions market?
  • What are the opportunities for digital therapeutic solutions in emerging markets?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to digital therapeutic solutions market?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of digital therapeutic solutions market and its likely evolution in the short-mid term and long term. 

Chapter 3 provides a general overview of the digital health sector, covering details related to the current and future trends in the domain. The chapter highlights the key concepts related to digital therapeutics. It also features a discussion on strategic initiatives undertaken by several organizations to support the development of digital solutions for treatment of chronic disorders. The chapter also provides an overview of the various product development pathways adopted by the companies in this field. 

Chapter 4  includes a detailed analysis of the current market landscape of over 230 digital therapeutic solutions, based on status of development, type of solution (combination offering of software application + device or AI or personal coach, and standalone software application), type of therapy (curative and preventive), purpose of solution (medication replacement and medication augmentation), target disease indication(s), therapeutic area(s), and target population. Further, the chapter provides an analysis of digital therapeutic solution developers, based on year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters. It also highlights the contemporary market trends in four schematic representations, which include [A] a bubble analysis comparing the leading players engaged in the development of digital therapeutic solutions based on the parameters, such as product portfolio strength, number of target indication(s) and company size, [B] a grid representation illustrating the distribution of the digital therapeutic solutions based on status of development, type of solution and therapeutic area, [C] an insightful tree map representation of the digital therapeutic solutions, distributed on the basis of therapeutic area and company size, and [D] a world map representation highlighting the regional distribution of developer companies.

Chapter 5 presents a detailed product competitiveness analysis of digital therapeutic solutions developed / under development for the most popular therapeutic areas taking into consideration the strength of product portfolio (based on the total number of digital therapeutic solutions being developed in that disease area) and key product specific parameters, such as status of development, type of solution, type of therapy, and purpose of solution.

Chapter 6 features elaborate profiles of prominent small-sized and mid-sized players that are either engaged in the development or have developed digital therapeutic solutions. Each company profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters and key members of the executive team), details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 7 provides a detailed analysis of more than 220 completed, ongoing and planned clinical studies of various digital therapeutic solutions, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status and trial focus, highlighting leading sponsors and leading digital therapeutic solutions (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful clinical end-points analysis (for trials initiated since 2018 for popular therapeutic areas).

Chapter 8 features an analysis of the investments made in the period between 2009 and 2020 (till June), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, highlighting the growing interest of the venture capital community and other strategic investors, in this domain. 

Chapter 9 features an in-depth analysis and discussion on the various partnerships inked between the players in this market, during the period, 2008-2020 (till May), covering marketing and distribution agreements, mergers / acquisitions, pilot product offerings, product / technology integration agreements,  product / technology licensing agreements, product development agreements, product evaluation agreements, product training agreements, research and development agreements and product development and commercialization agreements. 

Chapter 10 features a detailed analysis on the various business models and go-to-market strategies adopted by companies involved in this space. It also provides details on various channels adopted / being adopted by stakeholders in the industry to raise awareness and offer access to their proprietary products.

Chapter 11 presents a Bowman’s Strategy Clock framework in order to analyze the competitive position of various companies in the marketplace, taking into consideration the prices and different features of their products.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of digital therapeutic solutions market till 2030. We have segmented the market across [A] type of solution (combination offering of software application + device or AI or personal coach, and standalone software applications), [B] purpose of solution (medication replacement and medication augmentation), [C] type of therapy (curative and preventive), [D] distribution channels (B2C (patients) and B2B (healthcare providers, payers, employers and pharmaceutical companies)), [E] therapeutic areas (cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other disorders), and [F] key geographical regions (North America (the US and Canada), Europe (France, Germany, Italy, Spain and the UK), Asia-Pacific (Australia, China, India, Japan, and South Korea) and rest of the world). 

Chapter 13 highlights the impact of COVID-19 outbreak on the overall digital therapeutics market. In addition, it features a brief discussion on the key initiatives undertaken by big pharma players.

Chapter 14 features a review of the of the key aspects related to the remote digital monitoring and diagnostics solutions, including [A] a brief introduction to remote digital monitoring and diagnostics solutions, highlighting the key benefits and roadblocks [B] an assessment of the market landscape of remote digital monitoring and diagnostics solutions, based on various parameters, such as status of development, type of solution, target disease indication(s) and therapeutic area, along with the details on the companies that develop these solutions, highlighting year of establishment, company size and location of headquarters [C] detailed profiles of some of the key players that presently offer digital monitoring / diagnostic solutions for chronic disease management; each profile features a brief overview of the company (with information on year of establishment, number of employees, location of headquarters, lead investors, key partners and  members of the executive team), details of their product portfolio, recent developments and an informed future outlook, and [D] an insightful analysis on various capital investments that have been made into the digital monitoring / diagnostics domain.

Chapter 15 presents a discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall digital therapeutic solutions industry.

Chapter 16 offers an informative analysis of contemporary Google Trends in the time period between 2015 and 2020 (till July) and insights from the recent news articles related digital therapeutic solutions, indicating the increasing popularity of this domain. Furthermore, it highlights the potential future opportunities for players engaged in the development of such solutions.

Chapter 17 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Stephanie Tilenius (Co-Founder and Chief Executive Officer, Vida Health), Adam Kaufman (Chief Executive Officer, Canary Health), Vijay Ravindran (Chief Executive Officer, Floreo), Eran Ofir (Chief Executive Officer, Somatix), Edouard Gasser (Chief Executive Officer, Tilak Healthcare), Palakh R Sarogi (Vice President Marketing, Wellthy Therapeutics), Arani Sarkra (Senior Manager Consumer Marketing, Wellthy Therapeutics) and Yolande D’Mello (Marketing and Public Relations, Wellthy Therapeutics), Amelie Janson (Communication Manager, Voluntis), and Anonymous (Founder and Chief Executive Officer, UK based Small-Sized Company).

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 19 is an appendix, which contains the list of companies and organizations mentioned in the report

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1 Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions

3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification

3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics

3.5.2. Product Development and Commercialization Path for Digital Therapeutics 
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area 
4.2.7. Analysis by Target Population 

4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Prescription Requirement
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution

4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4 Analysis by Location of Headquarters

4.5. Leading Developers: Analysis by Number of Digital Therapeutics Solutions
4.6. Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
4.7. Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area
4.8. Tree Map Representation: Analysis by Therapeutic Area and Company Size
4.9. World Map Representation: Analysis of Regional Activity
4.10. Digital Therapeutics: Information on Additional Companies

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.4. Key Therapeutic Areas
5.4.1. Cardiovascular Disorders 
5.4.1.1. Product Competitiveness Analysis

5.4.2. Mental Health Problems
5.4.2.1. Product Competitiveness Analysis

5.4.3. Metabolic Disorders
5.4.3.1. Product Competitiveness Analysis

5.4.4. Neurological Disorders
5.4.4.1. Product Competitiveness Analysis

5.4.5. Substance Use Disorders
5.4.5.1. Product Competitiveness Analysis

5.4.6. Other Therapeutic Areas
5.4.6.1. Product Competitiveness Analysis

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive 
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook

6.5 Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook 

6.6. Mindmaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook 

6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook 

6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook 

6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook 

6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook

6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook

6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook 

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology

7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled and Trial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Players: Analysis by Number of Registered Trials
7.3.8 Leading Digital Therapeutic Solutions: Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Geographical Analysis by Number of Clinical Trials
7.3.12. Geographical Analysis by Trial Recruitment Status
7.3.13. Geographical Analysis by Enrolled Patient Population

7.4. Clinical End-Points Analysis

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding

8.3. Digital Therapeutics: Funding and Investment Analysis
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Therapy
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Geography 
8.3.7. Most Active Players: Analysis by Number of Funding Instances
8.3.8. Most Active Players: Analysis by Amount of Funding
8.3.9. Most Active Investors: Analysis by Number of Instances

8.4 Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS 
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: Recent Partnerships and Collaborations 
9.3.1. Analysis by Year of Partnership

9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Type of Partnership and Year of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size

9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Type of Partner and Year of Partnership
9.3.3.2. Analysis by Type of Partner and Type of Partnership

9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Therapy and Type of Partnership
9.3.4.2. Analysis by Type of Therapy and Type of Partner

9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Therapeutic Area and Year of Partnership
9.3.5.2 Analysis by Therapeutic Area and Type of Partner

9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and Intracontinental Agreements

10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models and Pricing Strategies
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model

10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks

11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock

11.3 Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis

11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Duration of Course
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2020-2030

12.4. Global Digital Therapeutics Market: Distribution by Type of Solution
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2020-2030
12.4.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2020-2030
12.4.3. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2020-2030
12.4.4. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2020-2030
12.4.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2020-2030
12.4.6. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2020-2030
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2020-2030

12.5. Global Digital Therapeutics Market: Distribution by Purpose of Solution
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2020-2030
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2020-2030

12.6. Global Digital Therapeutics Market: Distribution by Type of Therapy
12.6.1 Digital Therapeutics Market for Curative Therapy, 2020-2030
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2020-2030

12.7. Global Digital Therapeutics Market: Distribution by Business Model
12.7.1. Digital Therapeutics Market for B2C Model (Patients and Caregivers), 2020-2030
12.7.2. Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2020-2030

12.8. Global Digital Therapeutics Market: Distribution by Therapeutic Area
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2020-2030
12.8.2. Digital Therapeutics Market for Chronic Pain, 2020-2030
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2020-2030
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2020-2030
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2020-2030
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2020-2030
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2020-2030
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2020-2030
12.8.9. Digital Therapeutics Market for Other Disorders, 2020-2030

12.9. Global Digital Therapeutics Market: Distribution by Geography
12.9.1 Digital Therapeutics Market in North America, 2020-2030
12.9.1.1 Digital Therapeutics Market in the US, 2020-2030
12.9.1.2 Digital Therapeutics Market in Canada, 2020-2030

12.9.2 Digital Therapeutics Market in Europe, 2020-2030
12.9.2.1. Digital Therapeutics Market in France, 2020-2030
12.9.2.2. Digital Therapeutics Market in Germany, 2020-2030
12.9.2.3. Digital Therapeutics Market in Italy, 2020-2030
12.9.2.4. Digital Therapeutics Market in Spain, 2020-2030
12.9.2.5. Digital Therapeutics Market in the UK, 2020-2030
12.9.2.6. Digital Therapeutics Market in Rest of Europe, 2020-2030

12.9.3. Digital Therapeutics Market in Asia-Pacific, 2020-2030
12.9.3.1. Digital Therapeutics Market in Australia, 2020-2030
12.9.3.2. Digital Therapeutics Market in China, 2020-2030
12.9.3.3. Digital Therapeutics Market in India, 2020-2030
12.9.3.4. Digital Therapeutics Market in Japan, 2020-2030
12.9.3.5. Digital Therapeutics Market in South Korea, 2020-2030
12.9.3.6. Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030

12.9.4. Digital Therapeutics Market in Rest of the World, 2020-2030

13. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
13.1. Chapter Overview
13.2. Impact of Coronavirus Pandemic on Digital Therapeutics
13.2.1. Impact on Future Market Opportunity for Digital Therapeutic Solutions Market 

13.3. Recuperative Strategies for Developer Businesses
13.3.1. Strategies for Implementation in the Short / Mid Term
13.3.2. Strategies for Implementation in the Long Term

14. REMOTE DIGITAL MONITORING / DIAGNOSTIC SOLUTIONS 
14.1. Chapter Overview
14.2. An Introduction to Remote Digital Monitoring / Diagnostic Solutions
14.3. Remote Digital Monitoring / Diagnostic Solutions: Overall Market Landscape
14.3.1. Analysis by Status of Development
14.3.2. Analysis by Type of Solution
14.3.3. Analysis by Target Disease Indication(s)
14.3.4. Analysis by Therapeutic Area
14.3.5. Grid Representation: Analysis by Status of Development, Type of Solution, and Therapeutic Area

14.4. Remote Digital Monitoring / Diagnostic Solutions: List of Developers
14.4.1. Analysis by Year of Establishment
14.4.2. Analysis by Company Size
14.4.3. Analysis by Location of Headquarters

14.5. Remote Digital Monitoring / Diagnostic Solutions: Company Profiles
14.5.1. AliveCor
14.5.1.1. Company Snapshot
14.5.1.2. Product Portfolio
14.5.1.3. Recent Developments and Future Outlook

14.5.2. Bioserenity
14.5.2.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook

14.5.3. Cue
14.5.3.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook

14.5.4. Kinsa
14.5.4.1. Company Snapshot
14.5.4.2. Product Portfolio
14.5.4.3. Recent Developments and Future Outlook

14.6. Remote Digital Monitoring / Diagnostic Solutions: Funding and Investment Analysis
14.6.1. Types of Funding
14.6.2. Remote Digital Monitoring / Diagnostic Solutions: List of Funding and Investments
14.6.2.1. Analysis by Number of Funding Instances
14.6.2.2. Analysis by Amount Invested
14.6.2.3. Analysis by Type of Funding
14.6.2.4. Most Active Players: Analysis by Number of Funding Instances
14.6.2.5. Most Active Players: Analysis by Amount Invested
14.6.2.6. Most Active Investors: Analysis by Number of Funding Instances

14.7. Concluding Remarks

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Comparison of SWOT Factors 
15.2.1. Strengths
15.2.2. Weaknesses
15.2.3. Opportunities
15.2.4. Threats

16. DIGITAL SOLUTIONS: RECENT TRENDS AND FUTURE OPPORTUNITIES
16.1. Chapter Overview
16.2. Prevalent Trends Related to Digital Therapeutics
16.2.1. Emerging Focus Areas
16.2.2. Key Historical Trends
16.2.3. Geographical Distribution of Activity

16.3. Trends Shaping the Future of Digital Therapeutics
16.3.1. Digital Solutions Closing the Digital Gap 
16.3.2. Increasing Focus on Patient Centric Models  
16.3.3. Applicability across a Variety of Disease Indications
16.3.4. Increasing Emphasis on Real-World Evidence in Research and Development
16.3.5. Advances in IT and Computing Power to Foster Future Innovation
16.4. Improving the Future Health: Opportunities Beyond Digital Therapeutics

17. EXECUTIVE INSIGHTS
17.1. Chapter Overview 
17.2. Vida Health
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Stephanie Tilenius, Co-Founder and Chief Executive Officer

17.3. Canary Health
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Adam Kaufman, Chief Executive Officer

17.4. Floreo
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Vijay Ravidran, Chief Executive Officer

17.5. Somatix
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Eran Ofir, Chief Executive Officer 

17.6. Tilak Healthcare
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Edouard Gasser, Chief Executive Officer 

17.7. Wellthy Therapeutics
17.7.1. Company Snapshot
17.7.2. Interview Transcript: Palakh R Saraogi, Vice President Marketing, Arani Sarkra, Senior Manager Consumer Marketing, and Yolande D’Mello, Marketing and Public Relations

17.8. Voluntis
17.8.1. Company Snapshot
17.8.2. Interview Transcript: Amelie Janson, Communications Manager

17.9. Anonymous
17.9.1. Interview Transcript: Anonymous, Founder and Chief Executive Officer

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Major Causes for Chronic Diseases
Figure 3.2 Historical Timeline of Digital Health: Analysis of Google Trends
Figure 3.3 Internet of Things: General Framework
Figure 3.4 Internet of Things: Applications in Healthcare
Figure 3.5 Prescription Digital Therapeutics: Process Map
Figure 3.6 Characteristics of a Digital Therapeutic Program: An Illustration
Figure 4.1 Digital Therapeutics: Distribution by Status of Development
Figure 4.2 Digital Therapeutics: Distribution by Approval Year
Figure 4.3 Digital Therapeutics: Distribution by Type of Solution
Figure 4.4 Digital Therapeutics: Distribution by Type of Therapy
Figure 4.5 Digital Therapeutics: Distribution by Purpose of Solution
Figure 4.6 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Figure 4.7 Digital Therapeutics: Distribution by Target Indication(s)
Figure 4.8 Digital Therapeutics: Distribution by Therapeutic Area
Figure 4.9 Digital Therapeutics: Distribution by Target Population
Figure 4.10 Digital Therapeutics: Distribution by Prescription Requirement
Figure 4.11 Digital Therapeutics: Distribution by Duration of Course
Figure 4.12 Digital Therapeutics: Distribution by Cost of Solution
Figure 4.13 Digital Therapeutics Developers: Distribution by Year of Establishment
Figure 4.14 Digital Therapeutics Developers: Distribution by Company Size
Figure 4.15 Digital Therapeutics Developers: Distribution by Business Model Used
Figure 4.16 Digital Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.17 Leading Developers: Analysis by Number of Digital Therapeutics Solutions
Figure 4.18 Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
Figure 4.19 Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area
Figure 4.20 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Figure 4.21 World Map Representation: Regional Activity of Developers
Figure 5.1 Cardiovascular Disorders: Shift in Trends (2018 to 2020)
Figure 5.2 Product Competitiveness Analysis: Cardiovascular Disorders
Figure 5.3 Mental Health Problems: Shift in Trends (2018 to 2020)
Figure 5.4 Product Competitiveness Analysis: Mental Health Problems
Figure 5.5 Metabolic Disorders: Shift in Trends (2018 to 2020)
Figure 5.6 Product Competitiveness Analysis: Metabolic Disorders
Figure 5.7 Neurological Disorders: Shift in Trends (2018 to 2020)
Figure 5.8 Product Competitiveness Analysis: Neurological Disorders
Figure 5.9 Substance Use Disorders: Shift in Trends (2018 to 2020)
Figure 5.10 Product Competitiveness Analysis: Substance Use Disorders
Figure 5.11 Other Therapeutic Areas: Shift in Trends (2018 to 2020)
Figure 5.12 Product Competitiveness Analysis: Other Therapeutic Areas
Figure 6.1 Akili Interactive: Core Technologies and Benefits of Digital Products
Figure 6.2 WellDoc: Key Benefits of Diabetes Management Program
Figure 6.3 Wellthy Therapeutics: Diabetes Program
Figure 7.1 Key Methods to Validate Digital Therapeutic Solutions
Figure 7.2 Clinical Trial Analysis: Scope and Methodology
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled, Pre-2011-2020
Figure 7.6 Clinical Trial Analysis: Distribution by Study Design
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 7.8 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.10 Clinical Trial Analysis: Leading Industry Players
Figure 7.11 Clinical Trial Analysis: Leading Digital Therapeutic Solutions
Figure 7.12 Clinical Trial Analysis: Distribution by Focus Area
Figure 7.13 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.14 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Figure 7.15 Clinical Trial Analysis: Distribution by Number of Patients Enrolled and Therapeutic Area
Figure 7.16 Clinical Trial Analysis: Year-Wise Trend in Number of Patients Enrolled (in thousands) for Popular Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.18 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Figure 7.19 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.20 Clinical Trials Analysis: Key Clinical End-Points for Metabolic Disorders
Figure 7.21 Clinical Trial Analysis: Primary and Secondary Clinical End-Points for Metabolic Disorders
Figure 8.1 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Pre-2014-June-2020
Figure 8.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-June 2020
Figure 8.3 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-June 2020 (USD Million)
Figure 8.4 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-June 2020
Figure 8.5 Funding and Investment Analysis: Year-Wise Distribution by Type of Funding Pre-2014-June 2020
Figure 8.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-June 2020 (USD Million)
Figure 8.7 Funding and Investment Analysis: Year-Wise Distribution of Amount Invested and Type of Funding, Pre-2014-June 2020 (USD Million)
Figure 8.8 Funding and Investment Analysis: Summary of Amount Invested, Pre-2014-June 2020 (USD Million)
Figure 8.9 Funding and Investment Analysis: Distribution by Instances and Amount Invested by Type of Therapy, Pre-2014-June 2020 (USD Million)
Figure 8.10 Funding and Investment Analysis: Year-Wise Distribution of Instances by Type of Therapy, Pre-2014-June 2020
Figure 8.11 Funding and Investment Analysis: Cumulative Amount Invested (USD Million) by Type of Therapy, Pre-2014-June 2020
Figure 8.12 Funding and Investment Analysis: Distribution by Therapeutic Area, Pre-2014-June 2020
Figure 8.13 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, Pre-2014-June2020 (USD Million)
Figure 8.14 Funding and Investment Analysis: Distribution by Geography
Figure 8.15 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-June 2020
Figure 8.16 Most Active Players: Distribution by Number of Funding Instances, Pre-2014-June 2020
Figure 8.17 Most Active Players: Distribution by Amount Raised (USD Million), Pre-2014-June 2020
Figure 8.17 Most Active Investors: Distribution by Number of Funding Instances
Figure 8.18 Funding and Investment Summary, Pre-2014-Q1 2020 (USD Million)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2013-May 2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Therapy
Figure 9.10 Partnerships and Collaborations: Distribution by Type of Therapy and Type of Partnership
Figure 9.11 Partnerships and Collaborations: Distribution by Distribution by Type of Therapy and Type of Partner
Figure 9.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.13 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Figure 9.14 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Figure 9.15 Most Active Players: Distribution by Number of Partnerships
Figure 9.16 Partnerships and Collaborations: Regional Distribution
Figure 9.17 Partnerships and Collaborations: Country-Wise Distribution
Figure 9.18 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Go-to-Market Strategy: Commonly Used Social Media Platforms
Figure 10.2 Go-to-Market Strategy: Online / Print Media Platforms
Figure 10.3 Go-to-Market Strategy: Promotional Activities through Official Websites
Figure 10.4 Go-to-Market Strategy: Different Business Models Adopted
Figure 10.5 Go-to-Market Strategy: Promotional Activities through Product Websites
Figure 10.6 Go-to-Market Strategy: Key Marketing Strategies for New Entrants
Figure 10.7 Go-to-Market Strategy: Industry Stakeholder Opinions
Figure 11.1 Digital Therapeutics: Bowman Clock Pricing Strategy Matrix
Figure 11.2 Digital Therapeutics: Bowman Clock Pricing Strategy Graphical Interpretation
Figure 12.1 Overall Digital Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
Figure 12.2 Global Digital Therapeutics Market: Distribution by Type of Solution, 2020 and 2030
Figure 12.3 Digital Therapeutics Market for Standalone Software Applications, 2020-2030 (USD Million)
Figure 12.4 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2020-2030 (USD Million)
Figure 12.5 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2020-2030 (USD Million)
Figure 12.6 Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2020-2030 (USD Million)
Figure 12.7 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2020-2030 (USD Million)
Figure 12.8 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2020-2030 (USD Million)
Figure 12.9 Digital Therapeutics Market for Other Type of Solutions, 2020-2030 (USD Million)
Figure 12.10 Global Digital Therapeutics Market: Distribution by Purpose of Solution, 2020 and 2030
Figure 12.11 Digital Therapeutics Market for Medication Replacement Solutions, 2020-2030 (USD Million)
Figure 12.12 Digital Therapeutics Market for Medication Augmentation Solutions, 2020-2030 (USD Million)
Figure 12.13 Global Digital Therapeutics Market: Distribution by Type of Therapy, 2020 and 2030
Figure 12.14 Digital Therapeutics Market for Curative Therapy, 2020-2030 (USD Million)
Figure 12.15 Digital Therapeutics Market for Preventive Therapy, 2020-2030 (USD Million)
Figure 12.16 Global Digital Therapeutics Market: Distribution by Business Model, 2020 and 2030
Figure 12.17 Digital Therapeutics Market for B2C Model (Patients and Caregivers), 2020-2030 (USD Million)
Figure 12.18 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2020-2030 (USD Million)
Figure 12.19 Global Digital Therapeutics Market: Distribution by Therapeutic Area, 2020 and 2030
Figure 12.20 Digital Therapeutics Market for Cardiovascular Disorders, 2020-2030 (USD Million)
Figure 12.21 Digital Therapeutics Market for Chronic Pain, 2020-2030 (USD Million)
Figure 12.22 Digital Therapeutics Market for Mental Health Problems, 2020-2030 (USD Million)
Figure 12.23 Digital Therapeutics Market for Metabolic Disorders, 2020-2030 (USD Million)
Figure 12.24 Digital Therapeutics Market for Neurological Disorders, 2020-2030 (USD Million)
Figure 12.25 Digital Therapeutics Market for Respiratory Disorders, 2020-2030 (USD Million)
Figure 12.26 Digital Therapeutics Market for Sleep Disorders, 2020-2030 (USD Million)
Figure 12.27 Digital Therapeutics Market for Substance Use Disorders, 2020-2030 (USD Million)
Figure 12.28 Digital Therapeutics Market for Other Disorders, 2020-2030 (USD Million)
Figure 12.29 Global Digital Therapeutics Market: Distribution by Geography, 2020 and 2030
Figure 12.30 Digital Therapeutics Market in North America, 2020-2030 (USD Million)
Figure 12.31 Digital Therapeutics Market in the US, 2020-2030 (USD Million)
Figure 12.32 Digital Therapeutics Market in Canada, 2020-2030 (USD Million)
Figure 12.33 Digital Therapeutics Market in Europe, 2020-2030 (USD Million)
Figure 12.34 Digital Therapeutics Market in France, 2020-2030 (USD Million)
Figure 12.35 Digital Therapeutics Market in Germany, 2020-2030 (USD Million)
Figure 12.36 Digital Therapeutics Market in Italy, 2020-2030 (USD Million)
Figure 12.37 Digital Therapeutics Market in Spain, 2020-2030 (USD Million)
Figure 12.38 Digital Therapeutics Market in the UK, 2020-2030 (USD Million)
Figure 12.39 Digital Therapeutics Market in Rest of Europe, 2020-2030 (USD Million)
Figure 12.40 Digital Therapeutics Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 12.41 Digital Therapeutics Market in Australia, 2020-2030 (USD Million)
Figure 12.42 Digital Therapeutics Market in China, 2020-2030 (USD Million)
Figure 12.43 Digital Therapeutics Market in India, 2020-2030 (USD Million)
Figure 12.44 Digital Therapeutics Market in Japan, 2020-2030 (USD Million)
Figure 12.45 Digital Therapeutics Market in South Korea, 2020-2030 (USD Million)
Figure 12.46 Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030 (USD Million)
Figure 12.47 Digital Therapeutics Market in Rest of the World, 2020-2030 (USD Million)
Figure 12.48 Global Digital Therapeutics Market, 2020-2030: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 13.1 Global Digital Therapeutics Market 2020-2030: COVID-19 Impact Informed Scenario (USD Billion)
Figure 14.1 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Figure 14.2 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Figure 14.3 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Target Disease Indication
Figure 14.4 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Therapeutic Area
Figure 14.5 Grid Representation: Distribution by Status of Development, Type of Solution, and Therapeutic Area
Figure 14.6 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Year of Establishment
Figure 14.7 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Company Size
Figure 14.8 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Location of Headquarters
Figure 14.9 AliveCor: Benefits of Kardia
Figure 14.10 Cue: Key Elements of Digital Monitoring / Diagnostic Solutions
Figure 14.11 Kinsa: Product Portfolio
Figure 14.12 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Number of Funding Instances by Year
Figure 14.13 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested (USD Million)
Figure 14.14 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Instances by Type of Funding
Figure 14.15 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 14.16 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Funding Instances
Figure 14.17 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested (USD Million)
Figure 14.18 Remote Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Funding Instances
Figure 15.1 Digital Therapeutics SWOT Analysis: Overview
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Emerging Focus Areas: Google News
Figure 16.2 Digital Therapeutics: Analysis of Google Trends
Figure 16.3 Geographical Activity: Analysis of Google Trends
Figure 16.4 Digital Health: Opportunities beyond Digital Therapeutics

List Of Tables

Table 4.1 Digital Therapeutics: Information on Status of Development and Launch Year
Table 4.2 Digital Therapeutics: Information on Type of Solution
Table 4.3 Digital Therapeutics: Information on Type of Therapy and Purpose of Solution
Table 4.4 Digital Therapeutics: Information on Information on Target Indication(s), Therapeutic Area and Target Population
Table 4.5 Digital Therapeutic Solutions: Information on Prescription Requirement, Duration of Course and Cost of Solution
Table 4.4 Digital Therapeutics: List of Developers
Table 6.1 Digital Therapeutics: List of Companies Profiled
Table 6.2 Akili Interactive: Company Snapshot
Table 6.3 Akili Interactive: Digital Therapeutic Solutions Portfolio
Table 6.4 Akili Interactive: Recent Developments and Future Outlook
Table 6.5 Big Health: Company Snapshot
Table 6.6 Big Health: Digital Therapeutic Solutions Portfolio
Table 6.7 Big Health: Recent Developments and Future Outlook
Table 6.8 dreem: Company Snapshot
Table 6.9 dreem: Digital Therapeutic Solutions Portfolio
Table 6.10 dreem: Recent Developments and Future Outlook
Table 6.11 Kaia Health: Company Snapshot
Table 6.12 Kaia Health: Digital Therapeutic Solutions Portfolio
Table 6.13 Kaia Health: Recent Developments and Future Outlook
Table 6.14 Mindmaze: Company Snapshot
Table 6.15 Mindmaze: Digital Therapeutic Solutions Portfolio
Table 6.16 Omada Health: Company Snapshot
Table 6.17 Omada Health: Digital Therapeutic Solutions Portfolio
Table 6.18 Omada Health: Recent Developments and Future Outlook
Table 6.19 Pear Therapeutics: Company Snapshot
Table 6.20 Pear Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.21 Pear Therapeutics: Recent Developments and Future Outlook
Table 6.22 Vida Health: Company Snapshot
Table 6.23 Vida Health: Digital Therapeutic Solutions Portfolio
Table 6.24 Vida Health: Recent Developments and Future Outlook
Table 6.25 Voluntis: Company Snapshot
Table 6.26 Voluntis: Digital Therapeutic Solutions Portfolio
Table 6.27 Voluntis: Recent Developments and Future Outlook
Table 6.28 Welldoc: Company Snapshot
Table 6.29 Welldoc: Digital Therapeutic Solutions Portfolio
Table 6.30 Welldoc: Recent Developments and Future Outlook
Table 6.31 Wellthy Therapeutics: Company Snapshot
Table 6.32 Wellthy Therapeutics: Digital Therapeutic Solutions Portfolio
Table 6.33 Wellthy Therapeutics: Recent Developments and Future Outlook
Table 8.1 Digital Therapeutics: Funding and Investments, Information on Year of Investment, Type of Funding, Amount and Investor, till June 2020
Table 8.2 Digital Therapeutics: Funding and Investments, Information on Year of Establishment, Location of Headquarters of Recipients, Type of Therapy, and Therapeutic Area
Table 9.1 Digital Therapeutics: List of Collaborations, till May 2020
Table 9.2 Digital Therapeutics: Partnerships and Collaborations, Information on Type of Agreement (Region-wise and Geography-wise), till May 2020
Table 10.1 Digital Therapeutics: Summary of Marketing Strategies
Table 10.2 Go-to-Market Strategy: Product Specific Websites
Table 14.1 Remote Digital Monitoring / Diagnostic Solutions: List of Solutions
Table 14.2 Remote Digital Monitoring / Diagnostic Solutions: Information on Type of Solution
Table 14.3 Remote Digital Monitoring / Diagnostic Solutions: Information on Primary Disease Indication, Therapeutic Area and Diagnosis Indicators
Table 14.4 Remote Digital Monitoring / Diagnostic Solutions: List of Developers
Table 14.5 AliveCor: Company Snapshot
Table 14.6 AliveCor: Recent Developments and Future Outlook
Table 14.7 BioSerenity: Company Snapshot
Table 14.8 BioSerenity: Recent Developments and Future Outlook
Table 14.9 Cue: Company Snapshot
Table 14.10 Kinsa: Company Snapshot
Table 14.11 Kinsa: Recent Developments and Future Outlook
Table 14.12 Remote Digital Monitoring / Diagnostic Solutions: Funding and Investments
Table 14.13 Remote Digital Monitoring / Diagnostic Solutions: Summary of Investments
Table 17.1 Vida Health: Company Snapshot
Table 17.2 Canary Health: Company Snapshot
Table 17.3 Floreo: Company Snapshot
Table 17.4 Somatix: Company Snapshot
Table 17.5 Tilak Healthcare: Company Snapshot
Table 17.6 Wellthy Therapeutics: Company Snapshot
Table 17.7 Voluntis: Company Snapshot
Table 18.1 Digital Therapeutics: Distribution by Status of Development
Table 18.2 Digital Therapeutics: Distribution by Type of Solution
Table 18.3 Digital Therapeutics: Distribution by Type of Therapy
Table 18.4 Digital Therapeutics: Distribution by Purpose of Solution
Table 18.5 Digital Therapeutics: Distribution by Type of Therapy and Purpose of Solution
Table 18.6 Digital Therapeutics: Distribution by Target Indication(s)
Table 18.7 Digital Therapeutics: Distribution by Therapeutic Area
Table 18.8 Digital Therapeutics: Distribution by Target Population
Table 18.9 Digital Therapeutics: Distribution by Prescription Requirement
Table 18.10 Digital Therapeutics: Distribution by Duration of Course
Table 18.11 Digital Therapeutics: Distribution by Cost of Solution
Table 18.12 Digital Therapeutics Developers: Distribution by Year of Establishment
Table 18.13 Digital Therapeutics Developers: Distribution by Company Size
Table 18.14 Digital Therapeutics Developers: Distribution by Business Model Used
Table 18.15 Digital Therapeutics Developers: Distribution by Location of Headquarters
Table 18.16 Leading Developers: Analysis by Number of Digital Therapeutics Solutions
Table 18.17 Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
Table 18.18 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Table 18.19 World Map Representation: Regional Activity of Developers
Table 18.20 Cardiovascular Disorders: Shift in Trends (2018 to 2020)
Table 18.21 Mental Health Problems: Shift in Trends (2018 to 2020)
Table 18.22 Metabolic Disorders: Shift in Trends (2018 to 2020)
Table 18.23 Neurological Disorders: Shift in Trends (2018 to 2020)
Table 18.24 Substance Use Disorders: Shift in Trends (2018 to 2020)
Table 18.25 Other Therapeutic Areas: Shift in Trends (2018 to 2020)
Table 18.26 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020
Table 18.27 Clinical Trial Analysis: Distribution by Trial Phase
Table 18.28 Clinical Trial Analysis: Distribution by Trial Registration Year and Number of Patients Enrolled, Pre-2011-2020
Table 18.29 Clinical Trial Analysis: Distribution by Study Design
Table 18.30 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 18.31 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 18.32 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 18.33 Clinical Trial Analysis: Leading Industry Players
Table 18.34 Clinical Trial Analysis: Leading Digital Therapeutic Solutions
Table 18.35 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 18.36 Clinical Trial Analysis: Year-Wise Trend in Activity for Popular Therapeutic Areas
Table 18.37 Clinical Trial Analysis: Distribution by Number of Patients Enrollment and Therapeutic Area
Table 18.38 Clinical Trial Analysis: Year-Wise Trend in Patient Enrollments (in thousands) for Popular Therapeutic Areas
Table 18.39 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 18.40 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
Table 18.41 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 18.42 Funding and Investment Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding, Pre-2014-June-2020
Table 18.43 Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2014-June 2020
Table 18.44 Funding and Investment Analysis: Cumulative Amount Invested, Pre-2014-June 2020 (USD Million)
Table 18.45 Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2014-June 2020
Table 18.46 Funding and Investment Analysis: Year-Wise Distribution by Type of Funding, Pre-2014-June 2020
Table 18.47 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, Pre-2014-June 2020 (USD Million)
Table 18.48 Funding and Investment Analysis: Year-Wise Distribution of Amount Invested and Type of Funding, Pre-2014-June 2020 (USD Million)
Table 18.49 Funding and Investment Analysis: Summary of Amount Invested, Pre-2014-June 2020 (USD Million)
Table 18.50 Funding and Investment Analysis: Distribution by Instances and Amount Invested by Type of Therapy, Pre-2014-June 2020 (USD Million)
Table 18.51 Funding and Investment Analysis: Year-Wise Distribution of Instances by Type of Therapy, Pre-2014-June 2020
Table 18.52 Funding and Investment Analysis: Cumulative Amount Invested (USD Million) by Type of Therapy, Pre-2014-June 2020
Table 18.53 Funding and Investment Analysis: Distribution by Therapeutic Area, Pre-2014-June 2020 (USD Million)
Table 18.54 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, Pre-2014-April 2020 (USD Million)
Table 18.55 Funding and Investment Analysis: Distribution by Geography
Table 18.56 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, Pre-2014-June 2020
Table 18.57 Most Active Players: Distribution by Number of Funding, Pre-2014-June 2020
Table 18.58 Most Active Players: Distribution by Number of Amount Raised (USD Million), Pre-2014-June 2020
Table 18.59 Most Active Investors: Distribution by Number of Funding Instances
Table 18.60 Funding and Investment Summary, Pre-2014-June 2020 (USD Million)
Table 18.61 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2014-May 2020
Table 18.62 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.63 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 18.64 Partnerships and Collaborations: Distribution by Type of Partnership and Partner
Table 18.65 Partnerships and Collaborations: Distribution by Type of Partner
Table 18.66 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Table 18.67 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Table 18.68 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Table 18.69 Partnerships and Collaborations: Distribution by Type of Therapy
Table 18.70 Partnerships and Collaborations: Distribution by Type of Therapy and Type of Partnership
Table 18.71 Partnerships and Collaborations: Distribution by Distribution by Type of Therapy and Type of Partner
Table 18.72 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 18.73 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Table 18.74 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Table 18.75 Most Active Players: Distribution by Number of Partnerships
Table 18.76 Partnerships and Collaborations: Regional Distribution
Table 18.77 Partnerships and Collaborations: Country-Wise Distribution
Table 18.78 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 18.79 Go-to-Market Strategy: Commonly Used Social Media Platforms
Table 18.80 Go-to-Market Strategy: Online / Print Media
Table 18.81 Go-to-Market Strategy: Promotional Activities through Official Websites
Table 18.82 Go-to-Market Strategy: Different Business Models Adopted
Table 18.83 Go-to-Market Strategy: Promotional Activities through Product Websites
Table 18.84 Global Digital Therapeutics Market, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 18.85 Global Digital Therapeutics Market: Distribution by Type of Solution, 2020 and 2030
Table 18.86 Digital Therapeutics Market for Standalone Software Applications, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.87 Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.88 Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.89 Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.90 Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.91 Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.92 Digital Therapeutics Market for Other Type of Solutions, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.93 Global Digital Therapeutics Market: Distribution by Purpose of Solution, 2020 and 2030
Table 18.94 Digital Therapeutics Market for Medication Replacement Solutions, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.95 Digital Therapeutics Market for Medication Augmentation Solutions, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.96 Global Digital Therapeutics Market: Distribution by Type of Therapy, 2020 and 2030
Table 18.97 Digital Therapeutics Market for Curative Therapy, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.98 Digital Therapeutics Market for Preventive Therapy, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.99 Global Digital Therapeutics Market: Distribution by Business Model, 2020 and 2030
Table 18.100 Digital Therapeutics Market for B2C Model (Patients and, Caregivers), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.101 Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.102 Global Digital Therapeutics Market: Distribution by Therapeutic Area, 2020 and 2030
Table 18.103 Digital Therapeutics Market for Cardiovascular Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.104 Digital Therapeutics Market for Chronic Pain, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.105 Digital Therapeutics Market for Mental Health Problems, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.106 Digital Therapeutics Market for Metabolic Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.107 Digital Therapeutics Market for Neurological Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.108 Digital Therapeutics Market for Respiratory Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.109 Digital Therapeutics Market for Sleep Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.110 Digital Therapeutics Market for Substance Use Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.111 Digital Therapeutics Market for Other Disorders, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.112 Global Digital Therapeutics Market: Distribution by Geography, 2020 and 2030
Table 18.113 Digital Therapeutics Market in North America, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.114 Digital Therapeutics Market in the US, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.115 Digital Therapeutics Market in Canada, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.116 Digital Therapeutics Market in Europe, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.117 Digital Therapeutics Market in France, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.118 Digital Therapeutics Market in Germany, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.119 Digital Therapeutics Market in Italy, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.120 Digital Therapeutics Market in Spain, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.121 Digital Therapeutics Market in the UK, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.122 Digital Therapeutics Market in Rest of Europe, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.123 Digital Therapeutics Market in Asia-Pacific, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.124 Digital Therapeutics Market in Australia, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.125 Digital Therapeutics Market in China, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.126 Digital Therapeutics Market in India, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.127 Digital Therapeutics Market in Japan, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.128 Digital Therapeutics Market in South Korea, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.129 Digital Therapeutics Market in Rest of Asia-Pacific, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.130 Digital Therapeutics Market in Rest of the World, 2030-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 18.131 Digital Therapeutics Market 2030-2030: Conservative, Base and Optimistic Scenarios: COVID-19 Impact Informed Scenario (USD Billion)
Table 18.132 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Status of Development
Table 18.133 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Type of Solution
Table 18.134 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Target Disease Indication
Table 18.135 Remote Digital Monitoring / Diagnostic Solutions: Distribution by Therapeutic Area
Table 18.136 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Year of Establishment
Table 18.137 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Company Size
Table 18.138 Remote Digital Monitoring / Diagnostic Solution Providers: Distribution by Location of Headquarters
Table 18.139 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Number of Instances by Year
Table 18.140 Remote Digital Monitoring / Diagnostic Solutions: Cumulative Amount Invested (USD Million)
Table 18.141 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Instances by Type of Funding
Table 18.142 Remote Digital Monitoring / Diagnostic Solutions: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 18.143 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Number of Funding Instances
Table 18.144 Remote Digital Monitoring / Diagnostic Solutions: Most Active Players in terms of Amount Invested (USD Million)
Table 18.145 Remote Digital Monitoring / Diagnostic Solutions: Most Active Investors in terms of Number of Funding Instances

List Of Company

The following companies and organizations have been mentioned in the report. 

  1. 23andMe
  2. 2breathe Technologies
  3. 2Morrow
  4. 3.life
  5. 30Ventures
  6. 3M Ventures
  7. 500 Startups
  8. 5AM Ventures
  9. 7wire Ventures
  10. 98point6
  11. A Better Weigh
  12. AARDEX
  13. Abbott
  14. AbbVie
  15. Aberdare Ventures
  16. ACC
  17. Accel Diagnostics
  18. Accolade
  19. Adage Capital Management
  20. Adams Street Partners
  21. Advanced Circulatory Systems
  22. Advantage Consumer Healthcare
  23. AET Fund
  24. Aetna
  25. Afterbook
  26. Agro Group International Holdings
  27. AIMMED
  28. Airbus
  29. Akili Interactive
  30. Al-Ahli Hospital
  31. Alex therapeutics
  32. Alexandria Venture Investments
  33. Alfvén & Didrikson
  34. AliveCor
  35. All4Life
  36. Allen & Company
  37. Alsace Business Angels
  38. AltaMed
  39. Amalgam
  40. Amar Seva Sangam
  41. AME Cloud Partners
  42. American Association of Diabetes Educators
  43. American Diabetes Association
  44. American Society of Mechanical Engineers
  45. American Telemedicine Association
  46. Amgen Venture
  47. Amiko Digital Health
  48. Ampersand Health
  49. Ana Health
  50. Andreessen Horowitz
  51. Anorak Ventures
  52. Anthem
  53. Aperture Venture Partners
  54. Aplastic Anemia & MDS International Foundation
  55. Apple
  56. AppliedVR
  57. Apricity Health
  58. Arab Angel 
  59. Arboretum Ventures
  60. Areta Health
  61. Argon Global Healthcare
  62. Arthritis New Zealand
  63. Arthro Therapeutics
  64. Asabys Partners
  65. Ascensia Diabetes Care
  66. Ascension Brighton Center for Recovery
  67. Ascension Brighton Center for Recovery
  68. ascure STEPS
  69. Aspect Ventures
  70. Association of Municipalities of Ontario
  71. Astellas Pharma
  72. Asthma and Allergy Foundation of America
  73. AstraZeneca
  74. AT&T
  75. Athelas
  76. ATX Therapeutics
  77. Australasian College of Behavioural Optometrists (ACBO)
  78. Autism Learning Partners
  79. Axess4you
  80. BackerNation
  81. Baillie Gifford
  82. Balderton Capital
  83. Banco Sabadell
  84. Baseline Ventures
  85. Bayer
  86. Bayer G4A
  87. Beats Medical
  88. Beaumont Hospital
  89. BeCareLink
  90. Beehive Holdings
  91. BEENEXT
  92. BehaVr
  93. BeHealth Solutions
  94. BeneTalk
  95. Beneufit
  96. Berger & Moore Advisors
  97. Berklee's Institute for Creative Entrepreneurship
  98. Bessemer Venture Partners
  99. Beta Wave Consulting
  100. Betr Health
  101. Better Therapeutics
  102. Betterise 
  103. Betterise Health Tech
  104. Beyond Next Ventures
  105. Big Health
  106. Bigpoint
  107. Bimark
  108. BIOCORP
  109. Bioepic
  110. Biomark
  111. BioSerenity
  112. BioTrak Therapeutics
  113. Biotricity
  114. BioVentures Investors
  115. Birla Institute of Technology and Science
  116. BJC Healthcare
  117. Blackbird Ventures
  118. bLife
  119. Bloom Burton
  120. Blue Cross Blue Shield Venture Partners
  121. Blue Mesa Health
  122. Blue Note therapeutics
  123. Blue Shield of California
  124. Blue Spark Technologies
  125. Blueprint Health
  126. BOC Healthcare
  127. Bodyport
  128. Bold Health
  129. Bonit Capital
  130. Bose Ventures
  131. Boston Medical Center
  132. Boston University
  133. Boulder Care
  134. Bpifrance Large Venture
  135. Brain Power
  136. BrainCheck
  137. Brainmarc
  138. Breastlink
  139. Breed Reply
  140. BreezoMeter
  141. Breyer Capital
  142. Bridge Builders Collaborative
  143. Brilliant & Company
  144. Bristol-Myers Squibb
  145. Broadway Video Ventures
  146. Brooklands Capital Strategies
  147. BSdp
  148. Burrill & Company
  149. Burst IQ
  150. Burston
  151. Business Development Bank of Canada
  152. Business Health Care Group
  153. Caffeinated Capital
  154. Caixa Capital Micro II
  155. Caixa Capital TIC II
  156. Cambia Health Solutions
  157. Canaan Partners
  158. Canary Health
  159. Cancer Research Collaboration (CRC)
  160. Canepa Advanced Healthcare Fund
  161. Canvas Ventures
  162. CapDecisif Management
  163. Capricorn ICT Arkiv
  164. CareFirst
  165. Carrot Health
  166. Cascade Centers
  167. Caspar
  168. Castlight Health
  169. Catasys
  170. Cavendish Global
  171. CAVU Venture Partners
  172. Cedars-Sinai Medical Center
  173. Celebrate the Children
  174. Celgene
  175. CellScope
  176. Center for Autism Research (CAR)
  177. Center for Managing Chronic Disease, University of Michigan
  178. Center for the Advancement of Science in Space
  179. Central Illinois Angels
  180. Centria Healthcare
  181. Centria Healthcare Autism Services
  182. CF Hero
  183. CheckUp & Choices
  184. Chester County Intermediate Unit
  185. Chibagin Capital
  186. Chicago Ventures
  187. Children’s Community Health Plan
  188. Children’s Hospital of Philadelphia Center for Autism Research
  189. Children's Hospital of Philadelphia
  190. Cigna
  191. Cigna Ventures
  192. Cipla
  193. CIS Agriferts
  194. City Light Capital
  195. Civilization Ventures
  196. Claritas MindSciences
  197. CleanSlate Research and Education Foundation
  198. Click Therapeutics
  199. Clinakos
  200. CLSA
  201. CM-CIC Innovation
  202. Cognivive
  203. Cognoa
  204. Cohan Veteran’s Bioscience
  205. COLOPL VR Fund
  206. Columbia University Medical Center
  207. Columbia University Medical Center
  208. Community College System of New Hampshire
  209. Community Health Network of Connecticut
  210. Company K Partners
  211. Compassware
  212. Competitive Health
  213. Comprehensive Pain Specialists
  214. Connecticut Innovations
  215. CoreHealth Technologies
  216. Correlation Ventures
  217. COWEN
  218. CPS Capital Group
  219. CRCM Ventures
  220. Creandum
  221. Crista Galli Ventures
  222. Crohn's & Colitis Foundation
  223. Crossroads Treatment Centers
  224. CUCO Health
  225. Cue
  226. CureApp 
  227. Currae Healthtech
  228. CVS Health
  229. Cyberdine
  230. Cyrcadia Asia
  231. Cyrcadia Health
  232. dacadoo
  233. Dacuda
  234. Dai-ichi Life
  235. DAK Gesundheit 
  236. DancingMind
  237. DaneVest Tech Fund
  238. Dartmouth College
  239. Data Collective
  240. David Benshoof Klein
  241. daVinci Digital Therapeutics
  242. DCM
  243. Deerfield Management
  244. Delivering Scientific Innovation for Autism
  245. Dendera Ventures
  246. Dentsu Ventures
  247. Department of Veteran Affairs
  248. Dexcom
  249. DG Ventures
  250. Didriksons
  251. Digbi Health
  252. Digital Health
  253. Digitalis
  254. Digithera
  255. DigiTx Partners
  256. dLife
  257. DN Capital
  258. Doctor on Demand
  259. Doctoriya
  260. Doha Tech Angels
  261. Draper Fisher Jurvetson
  262. DrChrono
  263. Dreamit Ventures
  264. dreem
  265. Droobi Health
  266. dRx Capital
  267. Dthera Sciences
  268. dThx – Digital Therapeutics
  269. DTM
  270. Duke University School of Medicine
  271. Early Signal
  272. Echo Health Ventures
  273. eClinicalHealth
  274. Eco-Fusion
  275. EDBI
  276. Ehave
  277. Electric Lime 
  278. Electronics and Telecommunication Research Institute (ETRI)
  279. Elevation Capital
  280. Eli Lilly
  281. Ellume 
  282. Embr Labs
  283. Emory University
  284. Empatica
  285. Empire Capital Partners
  286. Endeavor Catalyst
  287. Endotronix
  288. Essex Woodlands
  289. European Commission
  290. European Pain Federation
  291. European School on Interdisciplinary Tinnitus Research
  292. Eva Ventures
  293. EVERSANA
  294. evivecare
  295. Evolve Foundation
  296. Excel Venture Management
  297. Exosystems
  298. Facebook
  299. Fearless Ventures
  300. Felicis Ventures
  301. Ferrer
  302. Fifty Years
  303. Finnish Student Health System (FSHS)
  304. FireStarter Fund
  305. FirstMark Capital
  306. FitBit
  307. FITJOY
  308. Flare Capital Partners
  309. Flatiron Investors
  310. Floodgate
  311. Floreo
  312. Florida Hospital
  313. Flying Health
  314. Focus DataScience
  315. Force Over Mass Capital
  316. Ford Motor Company
  317. Forward Partners
  318. Founder Collective
  319. Founders Factory
  320. Founders Fund
  321. Founders Health
  322. Fred Hutchinson Cancer Research Center
  323. Freelands Ventures
  324. Freestyle Capital
  325. Frist Center for Autism and Innovation
  326. Fruit Street
  327. Frumtak Ventures
  328. Fuerst Technology Innovations
  329. Future.Health
  330. FuturePeds
  331. FWD Takaful
  332. GAIA
  333. Gait Up
  334. GC VR Tracker Fund
  335. GE Ventures
  336. Gelt Venture Capital
  337. Genentech, a subsidiary of Roche
  338. General Catalyst
  339. Gennev
  340. Genoa Telepsychiatry
  341. George Washington University School of Medicine
  342. Georgian Partners
  343. Giant Leap
  344. Ginger
  345. GlaxoSmithKline
  346. Global Founders Capital
  347. GlobalYeast
  348. Go Clinic
  349. Go Digital KSA
  350. Golden Seeds
  351. Google
  352. Grammelot
  353. GrayMatters Health
  354. Great Heights Family Medicine
  355. Greg Badros
  356. Greycroft
  357. GreyGreen
  358. GrowX Venture Management
  359. GSR Ventures
  360. GuideWell Mutual Holding Corporation
  361. Haas F1 Team
  362. Habitual
  363. Hanmi IT
  364. Happify Health
  365. Harbor Pacific Capital
  366. Harrison Metal
  367. Healios
  368. Health Allliance Plan
  369. Health Care Originals
  370. Health Catalyst
  371. Health Mates
  372. Health Transformation Alliance
  373. HealthPartners
  374. HealthReveal
  375. HealthSlate
  376. HealthTap
  377. HealthX Ventures
  378. Healthy Trucking Association of America
  379. Heart Foundation
  380. Heartcore Capital
  381. Helios Orion
  382. HelloFresh
  383. Highmark Health
  384. Highmark Intera   ctive
  385. High-Tech Gründerfonds
  386. Higi
  387. Hikma Ventures
  388. Hinduja Group
  389. Hintsa Performance
  390. Hospices Civils de Lyon
  391. Hospital Universitario Reina Sofía
  392. Hudson River Capital Partners
  393. Human API
  394. Humana
  395. Hustle Fund
  396. Hyde Park Angels
  397. Hygieia
  398. I Mercury Capital
  399. I2A Fund
  400. IBB Beteiligungsgesellschaft
  401. iBionext 
  402. IBM
  403. Idinvest Partners
  404. IEEE
  405. iFeel Labs
  406. IIFL Select Equity Fund
  407. i-Mercury Capital
  408. Immortalana
  409. IMPACT Accelerator
  410. Impact First Investments
  411. IMS Health
  412. Incos Invest
  413. Index Ventures
  414. Initialized Capital
  415. inMotion VR
  416. Innogest Capital
  417. Innovate Health Tech NYC
  418. Innovate UK
  419. Innovation Capital
  420. Innovation Works
  421. Innovationsstarter Fonds Hamburg
  422. Institut de la Vision
  423. Insulet
  424. INTAGE Holdings
  425. Intel Capital
  426. Intermountain Healthcare
  427. Intermountain Ventures
  428. International Finance Corporation (IFC)
  429. Intervest
  430. Invest Detroit Ventures
  431. Invitalia Ventures
  432. Ironwood Pharmaceuticals
  433. iSeed Ventures
  434. iSono Health
  435. Israel Innovation Authority
  436. Itochu
  437. ITOCHU Technology Ventures
  438. Iwagin Jigyo Souzou Capital
  439. JamJar Investments
  440. Janssen Research & Development
  441. JAZZ Venture Partners
  442. Jett Capital Advisors
  443. JOGO Health
  444. John Hopki    ns University
  445. Johns Hopkins School of Hygiene and Public Health
  446. Johnson & Johnson
  447. Joint Academy
  448. Joslin Diabetes Center
  449. Joyable
  450. Joyance Partners
  451. Jumpstart Ventures
  452. Juvenile Diabetes Research Foundation T1D fund
  453. K Cube Ventures
  454. K2 Investment Partners
  455. KAC Health
  456. Kaia Health
  457. Kaiser Permanente Ventures
  458. Kakao Ventures
  459. Kapor Capital
  460. Karuna Labs
  461. Keio Innovation Initiative
  462. Kelvi
  463. Kentucky Science and Technology
  464. Kentucky Science Center
  465. Khosla Ventures
  466. Kiio
  467. King River Capital
  468. King's College London
  469. Kinnevik
  470. Kinsa
  471. Kleiner Perkins
  472. Kleiner Perkins Caufield & Byers
  473. KORE Digital Health Therapeutics
  474. Korea Advanced Institute of Science and Technology
  475. Koshidaka
  476. KTB Network
  477. Kurbo Health
  478. Kurma Diagnostics
  479. Kwit    
  480. Kyma Medical Technologies
  481. KYT-Know Your Treatment
  482. Laidir Foundation
  483. Landmark Benefits
  484. Lark Health
  485. Launchpad Digital Health
  486. Launchpad Venture Group
  487. LB Investment
  488. LBO France
  489. Learn Capital
  490. Leman Micro Devices
  491. LEO Innovation Lab
  492. Lief Therapeutics
  493. Life Sciences Discovery Fund
  494. LifeForce Capital
  495. Lifeforce Ventures
  496. Lifeline Ventures
  497. LifeScan
  498. LifeScan
  499. Lifespot Health
  500. Lifestyle & Wellness Medical Center
  501. LifeWave Biomedical
  502. Lightspeed Venture Partners
  503. Limbix
  504. LindaCare
  505. LionBirds
  506. Liquid 2 Ventures
  507. Lirio
  508. LiveBetter
  509. Livongo Health
  510. Louisiana Department of Health
  511. Luminopia
  512. Lumira Capital
  513. LumiraDx
  514. Lumosity
  515. Lund University
  516. Lux Capital
  517. Luz Saude
  518. Lyfebulb
  519. M Ventures
  520. M12
  521. M3 Ventures
  522. m8 Capital
  523. Macadamian
  524. Magellan Health
  525. Mahana Therapeutics
  526. MAIF Avenir
  527. Mangrove Capital Partners
  528. Manipal Education & Medical Group
  529. Manipal Education and Medical Group
  530. MAP Health Management
  531. Map My Health
  532. Maryland Technology Development Corporation (TEDCO)
  533. MassChallenge
  534. Maven Clinic 
  535. Maverick Ventures
  536. Max Healthcare
  537. Mayfield Fund
  538. McLaren Racing
  539. MDLIVE
  540. MediPeace Vietnam
  541. Medomnia
  542. MedRhythms
  543. MedTech Innovator
  544. Medtronic
  545. Meliora Technology
  546. Melon Health
  547. Memorado
  548. Merck
  549. Merck Global Health Innovation Fund
  550. Merck Ventures
  551. Mersey Care NHS Foundation Trust
  552. Meru Health
  553. metaMe
  554. Mevoked
  555. mHealth Technologies
  556. Mid-Atlantic Telehealth Resource Center 
  557. MindBeacon Group
  558. MindMaze
  559. MindSciences
  560. Mindset Health
  561. MINES & Associates
  562. Ministry of Health, Manatu Hauora
  563. MIO Global
  564. MIT Hacking Medicine
  565. MIT Venture Mentoring Service
  566. Mitsubishi UFJ Capital
  567. Mizuho Capital
  568. MJog
  569. Mobio Technologies
  570. Monarch Medical Technologies
  571. Montage Ventures
  572. Mori Trust
  573. Morningside Group
  574. Morningside Ventures
  575. Murray-Bertron
  576. My mhealth
  577. MyLife ID
  578. mySugr
  579. Naluri
  580. Naluri Hidup
  581. Nanobiosym Diagnostics
  582. Nanon
  583. NantHealth
  584. National Aeronautics and Space Administration
  585. National Cancer Institute
  586. National Cancer Research Institute
  587. National Institute of Biomedical Imaging and Bioengineering
  588. National Institute of Diabetes and Digestive and Kidney Diseases
  589. National Institute of Health
  590. National Institute of Mental Health and Neuro Sciences
  591. National Institute on Drug Abuse (NIDA)
  592. National Institutes of Health
  593. National Institutes on Aging
  594. National Multiple Sclerosis Society
  595. National Rheumatoid Arthritis Society
  596. National Science Foundation
  597. Navitus Health Solutions
  598. Nemaura Medical
  599. neuraltrain
  600. NeuroCure
  601. NeuroMetrix
  602. Neurotrack
  603. New Enterprise Associates
  604. New Mexico Retiree Health Care Authority (NMRHCA)
  605. New World Ventures
  606. Newsenselab
  607. Newtopia
  608. Nexeon MedSystems
  609. NextGen Venture Partners
  610. NGP Capital
  611. NHL Alumni Association
  612. NightWare
  613. Nike
  614. Nimble Ventures
  615. Nimbus Synergies
  616. Noaber Foundation
  617. nOCD.
  618. NODEHealth
  619. Nokia Growth Partners
  620. Noom
  621. North Texas Angel Network
  622. North York General Hospital
  623. Northwell Ventures
  624. Norwest Venture Partners
  625. Norwich Ventures
  626. Novant Health
  627. Novartis
  628. Novator Partners
  629. Novo Nordisk
  630. NOVOSI
  631. Nueon
  632. Nunaps 
  633. Nutrimental Healthcare
  634. NuvoAir
  635. Obvious Ventures
  636. Ocean Azul Partners
  637. Octopus Ventures
  638. Oklahoma Life Science Fund
  639. Omada Health
  640. Omidyar Technology Ventures
  641. OMRON Global
  642. Oncology Care Home Health
  643. Oncology Care Home Health Specialists
  644. Onduo
  645. Ontario Telemedicine (OTN)
  646. Ontario Telemedicine Network
  647. Open Medicine Institute
  648. Optum Ventures
  649. Oracle
  650. Orexo
  651. Orla DTx
  652. Oscilloscape
  653. OSF Ventures
  654. Otsuka America
  655. Otsuka Pharmaceutical
  656. Oxford Academic Health Science Network
  657. Oxford Finance
  658. Oxford University
  659. Pallasite Ventures
  660. Palo Alto Health Sciences
  661. Palo Alto Medical Foundation
  662. Parasail Health
  663. PatientsLikeMe
  664. Payor Logic
  665. PayPal
  666. PBJ Capital
  667. Pear Therapeutics
  668. Pegasus Tech Ventures
  669. Personal Health Solutions
  670. Pfizer
  671. Phenomenelle Angels
  672. Philips
  673. Pico Interactive
  674. Pinetree capital
  675. Pinterest
  676. Pioneer Fund
  677. Pittsburgh Life Sciences Greenhouse
  678. Pixie Scientific
  679. Pixvana
  680. Plan International
  681. Playground Global
  682. Plug and Play Tech Center
  683. PMV
  684. Podimetrics
  685. Pond Capital
  686. POPS! Diabetes Care
  687. Premera Blue Cross
  688. Presence Capital
  689. Prestige Health Choice
  690. Prism Healthcare
  691. Pritzker Group Venture Capital
  692. Prognos Health
  693. Progyny
  694. Promus Ventures
  695. Propeller Health
  696. Prority Health
  697. Proteus Digital Health
  698. Prototron
  699. Provenance Venture Forum
  700. Providence Health & Services
  701. Providence Ventures
  702. Psious
  703. Purdue University
  704. PureTech Health
  705. Qardio
  706. Qatar Development Bank
  707. Qatar Science & Technology Park
  708. Qiming Venture Partners
  709. Qualcomm Ventures
  710. Quinze-Vingts National Ophthalmology Hospital
  711. Quotas Beteiligungs
  712. R7 Partners
  713. Rally Health
  714. RB Investments
  715. ReachLink
  716. Reaktor Ventures
  717. Real Appeal
  718. Recruit Strategic Partners
  719. Red One Medical
  720. RedBrick Health
  721. Redmile Group
  722. Redox
  723. Reflectance Medical
  724. RegenConBio
  725. Renalis
  726. ResApp Health
  727. Research Foundation for The State University of New York
  728. Research Institute of Sant Pau
  729. Research Society for The Study of Diabetes in India (RSSDI)
  730. Restore Health
  731. Rethink Impact
  732. Retrofit
  733. Revon Systems
  734. Rewire
  735. RhythmiaBreath
  736. Ridgefield Public Schools 
  737. RMDY Health
  738. Roche
  739. Rock Health
  740. Romulus Capital
  741. Rothenberg Ventures
  742. RRE Ventures
  743. S.R. One
  744. Saama Capital India Advisors
  745. Safar Partners
  746. Safeguard Scientifics
  747. Sagamok Anishnawbek
  748. Saison Ventures
  749. Salesforce
  750. Salumedia
  751. Samsung
  752. Samsung Electronics
  753. Samsung Health
  754. Samsung Venture Investment
  755. Sandoz
  756. Sanitas
  757. Sanner
  758. Sanner Ventures
  759. Sano Intelligence
  760. Sanofi
  761. Sapphire Ventures
  762. Sarjan Health
  763. SBRI Healthcare
  764. Schoolhouse Partners
  765. Schooner Consulting
  766. SciFi VC
  767. Scrum Ventures
  768. Seattle Children’s Research Institute
  769. Second Nature
  770. Self Care Catalysts
  771. selfit health
  772. Selfit Medical
  773. Selfridges
  774. SENACTI
  775. Sennheiser
  776. Seoul National University Bundang Hospital
  777. Sequoia Capital
  778. Servier
  779. ShapeUp
  780. Sharecare
  781. Shenzhen JRW Technology
  782. Sherpa Capital
  783. Shionogi
  784. Shire
  785. Shire Pharmaceuticals
  786. Sidekick Health
  787. Signia Venture Partners
  788. Silicon Valley Bank
  789. Silicon Valley TMS
  790. SilverCloud Heath
  791. Sino Portfolio International
  792. Siren Care
  793. Slow Ventures
  794. Social Capital
  795. Social Starts
  796. Solera Health
  797. Somatix
  798. SOMPO Digital Lab
  799. Sompo Japan Nipponkoa
  800. Sonormed
  801. Sony Innovation Fund 
  802. Sophia Bendz
  803. SOS Ventures
  804. Sosna + Co
  805. Sound Life Sciences
  806. Sozo Ventures
  807. Sparknet (India) Marketing
  808. Sparo
  809. Spectrum Equity
  810. Spire
  811. Spotify
  812. Spring Ridge Ventures
  813. Sprint Accelerator
  814. St. Joseph's Care Group
  815. St. Jude Medical
  816. St. Luke's Health System
  817. St. Michael's Hospital
  818. Stanford University School of Medicine
  819. Stanley Park Ventures
  820. Startmate
  821. Startup Funding Club
  822. StartUp Health
  823. Startupbootcamp Digital Health Berlin
  824. Stateline Angels
  825. Steelcase
  826. Storm Ventures
  827. Stress Point Health
  828. SUSMED
  829. Sutter Health
  830. SV Life Sciences
  831. Sweet Capital
  832. Swift Medical
  833. Swing Therapeutics
  834. Swiss Re
  835. SyncMed 
  836. Synovation Medical Group
  837. TALi Digital
  838. Talkspace
  839. Technology Development Fund (TDF)
  840. Techstars
  841. Teijin
  842. Teladoc Health
  843. Telcare
  844. Telefonica
  845. Temasek
  846. Temasek Holdings
  847. The Aplastic Anemia & MDS International Foundation
  848. The Canadian Tire Wickenheiser World Female Hockey Festival
  849. The Cancer Research Collaboration
  850. The Carlyle Group
  851. The Chernin Group
  852. The Learning Corp
  853. The Research Foundation for The State University of New York 
  854. The Robotics Hub
  855. The Sync Project
  856. The Valley Fund
  857. The Venture Reality Fund
  858. The Vertical Group
  859. TheraTec
  860. Think Patients
  861. Think.Health
  862. Thrive Capital
  863. Tiatros
  864. TiE Boston Angels 
  865. Tilak Healthcare
  866. Tipp ecanoe County Government
  867. Tokyo Century
  868. Tower Capital Partners
  869. Train 24/8
  870. TransLink Capital
  871. TreeHouse Health
  872. Trend Forward Capital
  873. TrialSpark
  874. TriplePoint Capital
  875. TriplePoint Ventures
  876. Triumf Health
  877. True Ventures
  878. True Wealth Ventures
  879. TT Capital Partners
  880. Tuesday Capital
  881. Turnaround Health
  882. Twine Health
  883. Twitter
  884. U.S. Department of Veteran Affairs
  885. U.S. Venture Partners
  886. UCB
  887. Ultra Testing
  888. Uncork Capital
  889. Unique Nutrition Solutions
  890. United Healthcare
  891. University Medical Center Goettingen
  892. University of Bern
  893. University of California
  894. University of California Davis
  895. University of Hamburg
  896. University of London
  897. University of Lubeck
  898. University of Maryland
  899. University of Massachusetts Medical School
  900. University of Michigan
  901. University of Missouri
  902. University of Nebraska
  903. University of Nebraska Medical Center
  904. University of New York
  905. University of North Carolina
  906. University of Oxford
  907. University of Pennsylvania
  908. University of Rochester
  909. University of Texas at Dallas
  910. University of Texas Southwestern Medical School 
  911. University of Washington
  912. UpLift Health
  913. UPMC Enterprises
  914. VA Palo Alto Health Care System (VAPAHCS)
  915. Valerio Rosso
  916. Valeritas Holdings
  917. Validic
  918. Vanguard Medical Group
  919. Venrock
  920. Venture Kick
  921. Verily Life Sciences
  922. Vertical Group
  923. Vesalius Biocapital
  924. Vheda Health
  925. Vida Health 
  926. Vigo
  927. Village Global
  928. Vimeo
  929. Virgin Atlantic
  930. Virgin Pulse
  931. Virta Health
  932. VirtualScopics
  933. Virtue Health
  934. Vitadio
  935. Vital Art and Science
  936. Vital Labs
  937. Vitality Group
  938. Vivid Vision
  939. VNR Vignana Jyothi Institute of Engineering and Technology
  940. Volar Health
  941. Voluntis
  942. VSP Vision Care
  943. Wake Forest University
  944. Wakestream Ventures
  945. Wanxiang America
  946. Washington State Department of Health
  947. Washington University School of Medicine 
  948. Wayra
  949. WEA Trust
  950. Welkin Health
  951. Wellbe
  952. WellDoc
  953. WellDyneRx
  954. Wellington Management
  955. Wellthy Therapeutics
  956. Welltoc
  957. Welltrinsic Sleep Network
  958. West Coast Primary Health Organization
  959. Wicks Digital Health
  960. Wildflower Brands
  961. William Morris Endeavor
  962. William Osler Health System
  963. Windham Venture Partners
  964. Wisconsin Investment Partners
  965. Withings
  966. Wonderfull Wellness
  967. Wonju Severance Christian Hospital
  968. Workday Ventures
  969. Workit Health
  970. World Health Organization
  971. WP Global Partners
  972. WTF Health
  973. XING
  974. Xtreme Labs
  975. Y Combinator
  976. Yale University
  977. Z3VR
  978. Zaffre Investments
  979. Zillion
  980. ZOLL Medical
  981. Zyus

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com